Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2
- 9 June 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (4), 815-829
- https://doi.org/10.1111/j.1476-5381.2010.00913.x
Abstract
Fungal infection is prevalent in patients with diabetes mellitus. Thus, we investigated whether a pharmacokinetic interaction occurs between the anti-fungal agent itraconazole and the anti-glycaemic drug metformin, as both drugs are commonly administered together to diabetic patients and are metabolized via hepatic CYP3A subfamily in rats. Itraconazole (20 mg·kg(-1)) and metformin (100 mg·kg(-1)) were simultaneously administered i.v. and p.o. to rats. Concentrations (I) of each drug in the liver and intestine, maximum velocity (V(max)), Michaelis-Menten constant (K(m)) and intrinsic clearance (CL(int) ) for the disappearance of each drug, apparent inhibition constant (K(i) ) and [I]/K(i) ratios of each drug in the liver and intestine were determined. Also the metabolism of each drug in rat and human CYPs was measured in vitro. After simultaneous administration of both drugs, either i.v. or p.o., the total area under the plasma concentration-time curve from time zero to infinity (AUC)s of itraconazole and metformin were significantly greater than that of either drug administered alone. The metabolism of itraconazole and metformin was significantly inhibited by each other via CYP3A1 and 3A2 in rat and 3A4 in human microsomes. The significantly greater AUCs of itraconazole and metformin after i.v. administration of both drugs are probably due to competitive inhibition of the metabolism of each drug by each other via hepatic CYP3A1/2. Whereas after oral administration of both drugs, the significantly greater AUCs of each drug administered together than that of either drug alone is mainly due to competitive inhibition of intestinal metabolism of each drug by each other via intestinal CYP3A1/2.Keywords
This publication has 23 references indexed in Scilit:
- Pharmacokinetics of Itraconazole in Diabetic RatsAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2British Journal of Pharmacology, 2008
- Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: involvement of CYP1A1/2 in the formation of 1,3-DMUJournal of Pharmacy and Pharmacology, 2008
- Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitusJournal of the European Academy of Dermatology and Venereology, 2006
- Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metforminBritish Journal of Pharmacology, 2006
- Common Fungal Infections of the Feet in Patients with Diabetes MellitusDrugs & Aging, 2004
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 1996
- Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolismJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curveJournal of Pharmacokinetics and Biopharmaceutics, 1978
- The Determination of Enzyme Dissociation ConstantsJournal of the American Chemical Society, 1934